Open an account

Spero Therapeutics

SPRO · NASDAQ

$1.22+$0.10 (+8.93%)TodayMarket closed ·
Prev close $1.12

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company is headquartered in Cambridge, Massachusetts and currently employs 25 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Employees
25
Headquarters
Cambridge, Massachusetts
Listed
Nov 2, 2017
Sector
Health Care
Industry
Biotechnology
Website
sperotherapeutics.com

SPRO key statistics

Market cap
71.05M
Price-earnings ratio
8.00
Dividend yield
—
Average volume
910.15K
Volume
679.29K
Open price
$1.12
High today
$1.24
Low today
$1.11
52 Week high
$3.08
52 Week low
$1.08

Spero Therapeutics (SPRO) at a glance

As of Oct 20, 2026, Spero Therapeutics (SPRO) shares are priced at $1.22, giving the company a market cap of 71.05M and a price-to-earnings ratio of 8.00.

Today the stock has traded between $1.11 and $1.24. The current price is 9.9% above the day's low and 1.6% below its high.

Volume so far is 679.29K shares, below the average of 910.15K shares a day.

Over the past year Spero Therapeutics has ranged from $1.08 to $3.08, and now sits 7% of the way up that range.

Spero Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.16 per share against an estimate of -$0.1734.

The average analyst price target is $5.10, 318.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.10
Low
$4.04
Now
$1.22
High
$6.30

SPRO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 86.7% on average.

  1. Q3 FY24: reported -$0.32 per share against an estimate of -$0.3706
  2. Q4 FY24: reported -$0.38 per share against an estimate of -$0.3162
  3. Q1 FY25: reported -$0.25 per share against an estimate of -$0.561
  4. Q2 FY25: reported -$0.03 per share against an estimate of -$0.3876
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.255
  6. Q4 FY25: reported $0.53 per share against an estimate of -$0.204
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.1836
  8. Q2 FY26: reported -$0.16 per share against an estimate of -$0.1734

SPRO news

  • Press releasePRNewswire

    Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

  • Press releaseGlobe Newswire

    Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

  • Press releaseGlobe Newswire

    Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

  • Press releaseBusiness Wire

    Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

  • Vandana Singh

    GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

  • Press releaseBusiness Wire

    Compass Pathways Elects Kathleen Tregoning to Board of Directors

  • Insights Ahead: Spero Therapeutics's Quarterly Earnings

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

Similar companies

Companies in the same industry as Spero Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.